CeriBellvsJohnson & Johnson

CBLL and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CBLL

CeriBell, Inc.

$26.42

Value $994M

+1.07%
CBLL's page

CeriBell (CBLL) has a market value of $994M and Johnson & Johnson (JNJ) $681B. Over the last year, with dividends, CBLL moved +104.8% and JNJ +47.5%. Dividend yield: CBLL none, JNJ 1.87%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CBLL$994M

    JNJ$681B

    JNJ is 685 times CBLL

  • Revenue, 12 months

    CBLL$109M

    JNJ$99.3B

    JNJ is 914 times CBLL

  • Net income, 12 months

    CBLL-$74M

    JNJ$16.1B

  • Operating margin

    CBLL-69.8%

    JNJ–

  • ROIC

    CBLL-37.2%

    JNJ12.4%

    49.6 points apart

  • P/E

    CBLL–

    JNJ42.3

  • Dividend yield

    CBLL0.0%

    JNJ1.9%

    1.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CBLL+104.8%

JNJ+47.5%

100150200DecFebAprJunAugOct
Returns by period
PeriodCBLLWith dividendsJNJWith dividends
1 year since November 14, 2025+104.8%Price +104.8%+47.5%Price +44.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CBLLCeriBellJNJJohnson & Johnson

Valuation

CBLLJNJ
Valuation
Price$26.42$282.55
Market value$994M$681B
Enterprise value (EV)$897M$708B
P/E–42.3
P/E, 5-year median–21.9
P/B8.58.4
EV/EBIT–39.9
Free cash flow yield–3.0%

Results and growth

CBLLJNJ
Results and growth
Revenue, 12 months$109M$99.3B
Net income, 12 months-$74M$16.1B
Free cash flow, 12 months-$56M$20.6B
Earnings per share, 12 months-$1.94$6.59
Revenue growth, year on year36.1%6.1%
Revenue growth a year, past+40.3%over 2 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CBLLJNJ
Margins and returns on capital
Gross margin89.3%67.6%
Operating margin-69.8%–
Net margin-68.0%16.2%
ROIC-37.2%12.4%
ROE-52.3%19.7%

Balance sheet

CBLLJNJ
Balance sheet
Cash$118M$17.2B
Total debt$22M$44.7B
Net debt / EBITDA–1.1
Interest cover-47.4×18.0×

Dividends and buybacks

CBLLJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CBLL or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, CeriBell or Johnson & Johnson?

By market value, Johnson & Johnson ($681B) is about 684.7 times CeriBell ($994M), at today's prices.

How did CBLL and JNJ stock do over the last 1 years?

Since November 14, 2025, CBLL's price moved +104.8% and JNJ's +44.2%. With dividends: CBLL +104.8% (+104.8% a year), JNJ +47.5% (+47.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, CBLL or JNJ?

The dividend yield at today's price is none for CeriBell and 1.87% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, CeriBell or Johnson & Johnson?

Over the last twelve months, the net margin was -68.0% for CeriBell and 16.2% for Johnson & Johnson, and the operating margin -69.8% and –. Revenue was $109M and $99.3B.

Which is the better investment, CeriBell or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.